Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR1141)
Drug Name
R-1124
Synonyms
Netupitant; Netupitant(CID-6451149); CID 6451149; CID-6451149; CID6451149; Ro 67-31898/000; Ro-673189000; 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide; 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-o-tolylpyridin-3-yl)propanamide; 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide; 290297-26-6; 7732P08TIR; CHEBI:85155; CHEMBL206253; UNII-7732P08TIR
Indication Functional nausea/vomiting [ICD11: DD90] Phase 3 [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 578.6 Topological Polar Surface Area 39.7
Heavy Atom Count 41 Rotatable Bond Count 5
Hydrogen Bond Donor Count 0 Hydrogen Bond Acceptor Count 10
Cross-matching ID
PubChem CID
6451149
PubChem SID
11972336 ; 15109574 ; 43042117 ; 47206876 ; 50788120 ; 57370279 ; 103482309 ; 104063884 ; 114526492 ; 125683129 ; 126671554 ; 135246549 ; 137248756 ; 142494945 ; 162830915 ; 178102368 ; 179323031 ; 198988386 ; 210275497 ; 210281145 ; 223666980 ; 223771059 ; 226767714 ; 246332907 ; 249807117 ; 250163183 ; 251971119 ; 252215904 ; 252480189
ChEBI ID
CHEBI:85155
CAS Number
290297-26-6
TTD Drug ID
D0G3YC
Formula
C30H32F6N4O
Canonical SMILES
CC1=CC=CC=C1C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C
InChI
1S/C30H32F6N4O/c1-19-8-6-7-9-23(19)24-17-26(40-12-10-38(4)11-13-40)37-18-25(24)39(5)27(41)28(2,3)20-14-21(29(31,32)33)16-22(15-20)30(34,35)36/h6-9,14-18H,10-13H2,1-5H3
InChIKey
WAXQNWCZJDTGBU-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Monohydroxy netupitant DM005967
11657239
Oxidation - Hydrolyzationn 1 [4]
Netupitant N-Oxide DM005965
11848838
Oxidation - Oxidationn 1 [4]
N\demethylated netupitant DM005966
9915918
Oxidation - Demethylation 1 [4]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR006424 R-1124 Netupitant N-Oxide Oxidation - Oxidationn CYP3A4 ... [4]
MR006425 R-1124 N\demethylated netupitant Oxidation - Demethylation CYP3A4 ... [4]
MR006426 R-1124 Monohydroxy netupitant Oxidation - Hydrolyzationn CYP3A4 ... [4]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 2C9 (CYP2C9) DME0019 Homo sapiens
CP2C9_HUMAN
1.14.14.1
[2]
Cytochrome P450 2D6 (CYP2D6) DME0009 Homo sapiens
CP2D6_HUMAN
1.14.14.1
[2]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[3]
References
1 ClinicalTrials.gov (NCT01339260) An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting.
2 Effect of netupitant, a highly selective NK?receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Support Care Cancer. 2013 Oct;21(10):2879-87.
3 Complementary pharmacokinetic profiles of netupitant and palonosetron support the rationale for their oral fixed combination for the prevention of chemotherapy-induced nausea and vomiting. J Clin Pharmacol. 2019 Apr;59(4):472-487.
4 Netupitant PET imaging and ADME studies in humans

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.